US0327241065
© Globe Newswire
25.11.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Participation in December Investor Conferences
News Preview
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in mu...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.11.2025
ANAB
LISTED
NASDAQ
Anaptys Announces $100 Million Stock Repurchase Plan
News Preview
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company’s outs...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.11.2025
ANAB
LISTED
NASDAQ
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
News Preview
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. (“Tesaro”) has materially breached the parties’ Coll...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
10.11.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
News Preview
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab was safe and well tolerated but did not meet the primary endpoint of mean change from baseline in modified Mayo Score (mMS) o...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
04.11.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
News Preview
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ANAB
LISTED
NASDAQ
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
News Preview
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-breaking data from the robust, global 424-patient Phase 2b trial of rosnilimab, a selective and potent pathogenic T cell depleter, in rheumatoid arthrit...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
News Preview
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in rheumatoid arthritis (RA), was accepted for a late-breaking oral p...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.09.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
News Preview
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced today that its Board of Directors approved plans to explore separating its business into two independent, publicly traded companies, each poised for strong, susta...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.09.2025
ANAB
LISTED
NASDAQ
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
News Preview
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on Tuesday, Oct. 14....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Participation in September Investor Conferences
News Preview
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in mu...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.05.2025
ANAB
LISTED
NASDAQ
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
News Preview
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist target...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
ANAB
LISTED
NASDAQ
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
News Preview
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
24.03.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Stock Repurchase Plan
News Preview
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding com...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Participation in March Investor Conferences
News Preview
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in mu...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
News Preview
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.02.2025
ANAB
LISTED
NASDAQ
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
News Preview
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of P...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.02.2025
ANAB
LISTED
NASDAQ
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
News Preview
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
ANAB
LISTED
NASDAQ
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
ANAB
LISTED
NASDAQ
Anaptys Announces Participation in November and December Investor Conferences
News Preview
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multi...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
ANAB
LISTED
NASDAQ
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
News Preview
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2024
ANAB
LISTED
NASDAQ
Anaptys Announces Participation in September Investor Conferences
News Preview
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multi...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2024
ANAB
LISTED
NASDAQ
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
News Preview
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.08.2024
ANAB
LISTED
NASDAQ
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
News Preview
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
ANAB
LISTED
NASDAQ
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
News Preview
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2024 and provided a business update....
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2020
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 25, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2020
ANAB
LISTED
NASDAQ
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AnaptysBio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
News Preview
Los Angeles, California--(Newsfile Corp. - May 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AnaptysBio, Inc. ("AnaptysBio" or "the Company") (NASDAQ: ANAB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-...
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 25, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securities c...
Themefolio
Profiler
Peergroup
© Newsfile
22.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
22.05.2020
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
21.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 21, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. ("AnaptysBio, Inc.") (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019. You are hereby notified that a securities class a...
Themefolio
Profiler
Peergroup
© Newsfile
21.05.2020
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 21, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2020
ANAB
LISTED
NASDAQ
AnaptysBio Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - May 20, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ: ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi...
Themefolio
Profiler
Peergroup
© Newsfile
19.05.2020
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 19, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
19.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 19, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
17.05.2020
ANAB
LISTED
NASDAQ
AnaptysBio Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - May 17, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ: ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi...
Themefolio
Profiler
Peergroup
© Newsfile
15.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 15, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. ("AnaptysBio, Inc.") (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019. You are hereby notified that a securities c...
Themefolio
Profiler
Peergroup
© Newsfile
14.05.2020
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 14, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Klein Law Firm LogoClass Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26...
Themefolio
Profiler
Peergroup
© Newsfile
14.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 14, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
29.04.2020
ANAB
LISTED
NASDAQ
MAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AnaptysBio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
News Preview
Los Angeles, California--(Newsfile Corp. - April 29, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AnaptysBio, Inc. ("AnaptysBio" or "the Company") (NASDAQ: ANAB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10...
Themefolio
Profiler
Peergroup
© Newsfile
14.04.2020
ANAB
LISTED
NASDAQ
AnaptysBio Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - April 14, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ: ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faru...
Themefolio
Profiler
Peergroup
© Newsfile
13.04.2020
ANAB
LISTED
NASDAQ
AnaptysBio Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - April 13, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (NASDAQ: ANAB) ("Anaptys" or the "Company") of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruq...
Themefolio
Profiler
Peergroup
© Newsfile
03.04.2020
ANAB
LISTED
NASDAQ
AnaptysBio Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In AnaptysBio, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - April 3, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (NASDAQ: ANAB) ("Anaptys" or the "Company") of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faru...
Themefolio
Profiler
Peergroup
© Newsfile
01.04.2020
ANAB
LISTED
NASDAQ
AnaptysBio Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - April 1, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (NASDAQ: ANAB) ("Anaptys" or the "Company") of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
